In the past week, TMO stock has gone down by -1.35%, with a monthly gain of 0.41% and a quarterly surge of 7.19%. The volatility ratio for the week is 1.86%, and the volatility levels for the last 30 days are 1.65% for Thermo Fisher Scientific Inc. The simple moving average for the last 20 days is -0.31% for TMO stock, with a simple moving average of 7.57% for the last 200 days.
Is It Worth Investing in Thermo Fisher Scientific Inc. (NYSE: TMO) Right Now?
Thermo Fisher Scientific Inc. (NYSE: TMO) has a higher price-to-earnings ratio of 37.85x compared to its average ratio. TMO has 36-month beta value of 0.78. Analysts have mixed views on the stock, with 6 analysts rating it as a “buy,” 8 as “overweight,” 1 as “hold,” and 0 as “sell.”
3 Tiny Stocks Primed to Explode
The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free
Sponsored
The public float for TMO is 381.34M, and currently, short sellers hold a 0.93% ratio of that float. The average trading volume of TMO on September 19, 2024 was 1.52M shares.
TMO) stock’s latest price update
The stock of Thermo Fisher Scientific Inc. (NYSE: TMO) has decreased by -0.06 when compared to last closing price of 610.49. Despite this, the company has experienced a -1.35% fall in its stock price over the last five trading sessions. globenewswire.com reported 2024-09-18 that Biognosys’ Spectronaut®, the leading vendor-agnostic software for DIA proteomics, is now directly available from Thermo Fisher Scientific under a reselling agreement End users can get access to Thermo Scientific mass spectrometry systems and Biognosys’ Spectronaut software via a single offer issued by Thermo Fisher Thermo Fisher will directly quote and sell Biognosys’ Spectronaut software from its product catalog ZURICH and NEWTON, Mass., Sept. 18, 2024 (GLOBE NEWSWIRE) — Biognosys, a leading inventor and provider of software solutions for mass spectrometry-based proteomics data analysis, today announced the rollout of a Value-added Reselling agreement for Biognosys’ Spectronaut® software with Thermo Fisher Scientific.
Analysts’ Opinion of TMO
Many brokerage firms have already submitted their reports for TMO stocks, with Wells Fargo repeating the rating for TMO by listing it as a “Overweight.” The predicted price for TMO in the upcoming period, according to Wells Fargo is $670 based on the research report published on August 28, 2024 of the current year 2024.
Jefferies, on the other hand, stated in their research note that they expect to see TMO reach a price target of $650. The rating they have provided for TMO stocks is “Buy” according to the report published on June 03rd, 2024.
Citigroup gave a rating of “Neutral” to TMO, setting the target price at $620 in the report published on March 18th of the current year.
TMO Trading at 2.79% from the 50-Day Moving Average
After a stumble in the market that brought TMO to its low price for the period of the last 52 weeks, the company was unable to rebound, for now settling with -2.83% of loss for the given period.
Volatility was left at 1.65%, however, over the last 30 days, the volatility rate increased by 1.86%, as shares sank -0.72% for the moving average over the last 20 days. Over the last 50 days, in opposition, the stock is trading +14.71% upper at present.
During the last 5 trading sessions, TMO fell by -1.35%, which changed the moving average for the period of 200-days by +23.07% in comparison to the 20-day moving average, which settled at $611.79. In addition, Thermo Fisher Scientific Inc. saw 14.95% in overturn over a single year, with a tendency to cut further gains.
Insider Trading
Reports are indicating that there were more than several insider trading activities at TMO starting from CASPER MARC N, who sale 10,000 shares at the price of $608.74 back on Sep 03 ’24. After this action, CASPER MARC N now owns 121,192 shares of Thermo Fisher Scientific Inc., valued at $6,087,445 using the latest closing price.
CASPER MARC N, the Chairman & CEO of Thermo Fisher Scientific Inc., sale 10,000 shares at $608.15 during a trade that took place back on Sep 04 ’24, which means that CASPER MARC N is holding 121,192 shares at $6,081,529 based on the most recent closing price.
Stock Fundamentals for TMO
Current profitability levels for the company are sitting at:
- 0.17 for the present operating margin
- 0.41 for the gross margin
The net margin for Thermo Fisher Scientific Inc. stands at 0.15. The total capital return value is set at 0.09. Equity return is now at value 13.64, with 6.46 for asset returns.
Based on Thermo Fisher Scientific Inc. (TMO), the company’s capital structure generated 0.43 points at debt to capital in total, while cash flow to debt ratio is standing at 0.26. The debt to equity ratio resting at 0.75. The interest coverage ratio of the stock is 10.49.
Currently, EBITDA for the company is 10.72 billion with net debt to EBITDA at 2.83. When we switch over and look at the enterprise to sales, we see a ratio of 6.17. The receivables turnover for the company is 4.49for trailing twelve months and the total asset turnover is 0.43. The liquidity ratio also appears to be rather interesting for investors as it stands at 1.72.
Conclusion
To put it simply, Thermo Fisher Scientific Inc. (TMO) has had a better performance in recent times. Analysts have a bullish opinion on the stock, with some rating it as a “buy” and others as a “hold”. It is worth mentioning that the stock is currently trading in close proximity to its 50-day moving average and its 52-week high.
